Harvard Medical School, Boston, MA, USA.
Best Pract Res Clin Haematol. 2012 Dec;25(4):437-41. doi: 10.1016/j.beha.2012.10.006. Epub 2012 Nov 12.
There are several strategies for improving post-remission therapy in acute myeloid leukemia (AML). One is a risk-adapted strategy for younger adults in which patients with non-favorable characteristics based on cytogenetics and genetics are allocated to allogeneic stem cell transplantation and others receive intensive high-dose ara-C-based therapies. Additional genetic data and/or minimal residual disease level may prove useful in post-remission therapeutic choice. Future approaches, badly needed in older AML patients, may include the addition of new agents to currently used therapies or maintenance with DNA methyltransferase inhibitors.
有几种策略可以改善急性髓系白血病（AML）的缓解后治疗。一种是针对年轻成年人的风险适应策略，根据细胞遗传学和遗传学的非有利特征，将患者分配给异基因干细胞移植，而其他患者则接受强化高剂量阿糖胞苷为基础的治疗。额外的遗传数据和/或微小残留病水平可能在缓解后治疗选择中证明有用。在老年 AML 患者中迫切需要的未来方法可能包括在现有治疗中添加新药物或使用 DNA 甲基转移酶抑制剂进行维持治疗。
